DMAARDrugs Made In America Acquisition Corp.
0.1000USD-18.23%Mkt Cap: —P/E: —Last update: 2026-06-12
Drugs Made In America Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business …
Industry Peers
Diversified Financial ServicesNHIC
NewHold Investment Corp.303.74MUSDP/E 55.0
FACT
FACT II Acquisition Corp259.02MUSDP/E 56.1
ROC
ROC Energy Acquisition Corp. Common Stock85.10MUSD—
ISRL
Israel Acquisitions Corp Class A Ordinary Shares78.77MUSD—
BPAC
Blueport Acquisition Ltd74.73MUSDP/E 506.0
APLMW
Apollomics, Inc.44.05MUSD—
35.94MUSD—
KAC-P
Kalon Acquisition Corp.215.6KCAD—
Indicators:|
Key Statistics
Company
Market Cap—
Enterprise Value—
Revenue (TTM)—
Gross Profit—
Net Income (TTM)5.94M USD
Revenue/Share—
Last Price0.1000 USD
Fiscal Year End—
MR Quarter—
Employees—
CountryUS
SectorFinancial Services
IndustryDiversified Financial Services
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B-0.47
EPS (TTM)—
EPS (Forward)—
52W Range
0.10000% of range0.1300
52W High0.1300 USD
52W Low0.1000 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE—
ROA-1.46%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-539.19K USD
CapEx (TTM)—
FCF Margin—
FCF Yield—
Net Debt-6.14K USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio0.03
Quick Ratio0.02
Book Value/Sh-0.2150 USD
Cash/Share0.0000 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.20.40M
Float27.31M
Insiders—
Institutions—
Technical
SMA 50—
SMA 200—
Beta—
S&P 52W Chg23.71%
Avg Vol (30d)28.66K
Avg Vol (10d)—
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—